Insider trading

Period: 120 months Stock: CTMX Role: Other officers × + Add filter Clear all
Views & alerts

Save your view. Keep the filter you have built, and get an email when a new filing matches it. A free account does both.

When

Period

How far back the list reaches. Filings arrive days after the trade, so the newest rows always lag a little.

31 decisions over 120 months
Who

Role

The position the person holds at the company, read from the title on the filing. A chief executive who is also a director counts as the chief executive.

31 decisions over 120 months Remove this filter
The trade

Type of trade

Purchases, sales, or cluster buys: companies where 3 or more insiders bought within 30 days. The number beside each is what that choice would give.

31 decisions over 120 months
The trade

Minimum amount

Hides rows under this value. The amount is the shares traded times the price on the filing.

31 decisions over 120 months
The trade

Plan

  • Discretionary: they chose to sell that week.
  • Scheduled: a 10b5-1 plan fixed the sale months in advance, so the timing says nothing about what they knew.
  • Not stated: filed before the SEC added the box in April 2023, which is most of the older half of this database.
31 decisions over 120 months
The trade

Share of their own holding

How much of what they already held the trade moved. Selling a tenth of a stake is not the same act as selling all of it.

At least
31 decisions over 120 months
Ownership

What the chief executive holds

The value of the chief executive’s stock measured against base salary. The salary comes from the company’s own proxy. Companies with no figure are in neither direction.

31 decisions over 120 months
Stock
Insider
Type ?
Why it stands out
17 Mar 2026
BELVIN MARCIA SVP, Chief Scientific Officer
Sold at will
$202.27K 31,492 at 6.42
9.5%
Not planned
17 Mar 2026
Chu Yu-Waye Chief Medical Officer
Sold at will
$136.68K 21,279 at 6.42
10.1%
Not planned
16 Jun 2025
BELVIN MARCIA SVP, Chief Scientific Officer
Sold at will
$37.33K 13,884 at 2.69
4.9%
Not planned
18 Mar 2025
BELVIN MARCIA SVP, Chief Scientific Officer
Sold at will
$11.69K 19,512 at 0.60
7.3%
Not planned
18 Mar 2025
ROWLAND LLOYD A General Counsel
Sold at will
$6.11K 10,203 at 0.60
7.8%
Not planned
18 Mar 2025
Chu Yu-Waye Chief Medical Officer
Sold at will
$2.41K 4,025 at 0.60
2.9%
Not planned
20 Aug 2024
ROWLAND LLOYD A General Counsel
Sold at will
$5.14K 4,181 at 1.23
3.1%
Not planned
20 Aug 2024
BELVIN MARCIA SVP, Chief Scientific Officer
Sold at will
$5.14K 4,181 at 1.23
2.3%
Not planned
20 Aug 2024
Landau Jeffrey B Chief Business Officer
Sold at will
$5.14K 4,181 at 1.23
3.4%
Not planned
19 Mar 2024
BELVIN MARCIA SVP, Chief Scientific Officer
Sold at will
$26.68K 12,795 at 2.09
7.1%
Not planned
19 Mar 2024
Landau Jeffrey B Chief Business Officer
Sold at will
$13.69K 6,562 at 2.09
5.6%
Not planned
19 Mar 2024
ROWLAND LLOYD A General Counsel
Sold at will
$10.99K 5,268 at 2.09
4.3%
Not planned
19 Mar 2024
Ogden Christopher SVP, Finance and Accounting
Sold at will
$6.20K 2,971 at 2.09
3.4%
Not planned
20 Dec 2023
ROWLAND LLOYD A General Counsel
Sold at will
$5.63K 4,077 at 1.38
4.0%
Not planned
20 Dec 2023
Landau Jeffrey B Chief Business Officer
Sold at will
$5.63K 4,077 at 1.38
4.5%
Not planned
20 Dec 2023
BELVIN MARCIA SVP, Chief Scientific Officer
Sold at will
$5.63K 4,077 at 1.38
2.6%
Not planned
20 Dec 2023
Ogden Christopher SVP, Finance and Accounting
Sold at will
$2.75K 1,990 at 1.38
3.9%
Not planned
22 Sep 2023
ROWLAND LLOYD A General Counsel
Sold at will
$7.14K 5,486 at 1.30
6.4%
Not planned
22 Sep 2023
Landau Jeffrey B Chief Business Officer
Sold at will
$5.36K 4,119 at 1.30
5.1%
Not planned
22 Sep 2023
BELVIN MARCIA SVP, Chief Scientific Officer
Sold at will
$5.36K 4,119 at 1.30
2.7%
Not planned
16 Mar 2023
Peterson Amy C. EVP, Chief Development Officer
Sold at will
$8.42K 4,257 at 1.98
6.8%
Not planned
16 Mar 2023
ROWLAND LLOYD A General Counsel
Sold at will
$4.03K 2,037 at 1.98
2.8%
Not planned
16 Mar 2023
Ogden Christopher SVP, Finance and Accounting
Sold at will
$1.02K 516 at 1.98
1.3%
Not planned
20 Jul 2022
Peterson Amy C. EVP, Chief Development Officer
Sold, plan not stated
$10.61K 7,463 at 1.42
10.6%
20 Jul 2022
ROWLAND LLOYD A General Counsel
Sold, plan not stated
$7.97K 5,602 at 1.42
11.4%
20 Jul 2022
HANNAH ALISON L. Chief Medical Officer
Sold, plan not stated
$7.97K 5,602 at 1.42
14.9%
20 Jul 2022
Landau Jeffrey B Chief Business Officer
Sold, plan not stated
$5.98K 4,206 at 1.42
12.0%
4 Mar 2019
ROWLAND LLOYD A General Counsel
Bought
$92.97K 9,000 at 10.33
919%
First buy on file
2 Mar 2018
HUMPHREY RACHEL Chief Medical Officer
Sold, plan not stated
$484.80K 16,160 at 30.00
34.8%
28 Feb 2018
HUMPHREY RACHEL Chief Medical Officer
Sold, plan not stated
$715.20K 23,840 at 30.00
44.1%
4 Oct 2017
Kavanaugh William Michael CSO, Head Res.&Non-Clin. Dev.
Sold, plan not stated
$1.18M 48,368 at 24.34
77.7%
Sold half or more
Showing 1–31 of 31.